Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Capitol Hill In Brief

This article was originally published in The Gray Sheet

Executive Summary

MDUFMA oversight: Senate HELP Committee Chairman Judd Gregg (R-N.H.) is committed to ensuring that FDA receives the maximum funding needed to implement the Medical Device User Fee & Modernization Act, health counsel Steve Irizarry affirms at the Banc of America Securities Washington Healthcare Policy meeting May 7. "It's something that is apparently important to the Administration, to the FDA and to my boss, and we'll do everything we can, particularly my boss, [who] is an appropriator, to make sure FDA gets the requisite amounts," Irizarry pledged...
Advertisement

Related Content

Project BioShield Compromise In House Could Serve As Senate Template
Project BioShield Compromise In House Could Serve As Senate Template
Bioshield Legislation Headed To Senate Floor Despite Objections Of Sen. Byrd
Bioshield Legislation Headed To Senate Floor Despite Objections Of Sen. Byrd
Advertisement
UsernamePublicRestriction

Register

MT018349

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel